- Home
- CNTY vs CNTB Comparison
CNTY vs CNTB Comparison
Compare CNTY & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | CNTB |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 140.4M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNTY | CNTB |
|---|---|---|
| Price | $1.11 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.00 | ★ $8.67 |
| AVG Volume (30 Days) | 34.6K | ★ 1.7M |
| Earning Date | 05-08-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | $64,000.00 |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.11 | $1.06 |
| 52 Week High | $2.73 | $3.82 |
Technical Indicators
Market Signals| Indicator | CNTY | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 29.96 |
| Support Level | N/A | N/A |
| Resistance Level | $1.33 | $2.78 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.